Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Survey: Salaries up 9% in medical device sales
Salaries for medical device sales representatives are up 9% in 4 years and 5% over last year, according to a survey of some 1,200 medtech sales agents by MedReps.com.
The average medical device sales salary tops $158,000 (median $145,000), including commissions and bonus, according to the jobs board’s survey of more than 3,000 medical sales professionals. Sales directors and vice presidents predictably earned the most, at an average of nearly $234,000 a year. Field sales personnel earned an annual average of about $155,000, according to the survey. Read more
2. Boston Scientific touts Vercise DBS for Parkinson’s
Boston Scientific said a 15-patient study of its Vercise deep-brain stimulation device showed that shorter pulses may be better in treating Parkinson’s disease than conventional, wider pulses.
Results from the Custom-DBS trial, presented at the International Congress of Parkinson’s Disease & Movement Disorders in Stockholm by primary principal investigator Dr. Jens Volkmann, showed that the shorter pulse widths expands the available range of current to provide therapy without side effects, according to a press release. Read more
1. Medtronic files final PMA module for In.Pact Admiral drug-eluting balloon
Medtronic said it submitted the final module for its bid for FDA approval of its In.Pact Admiral drug-eluting balloon for treating peripheral artery disease.
The submission includes data demonstrating “superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (primary patency) at 12 months ever reported for the interventional treatment of peripheral artery disease,” according to a press release. Read more
